Cypralis Limited

Neurovive Pharmaceuticals Ab

Neurovive Pharmaceutical Ab

Hans Georg Fliri

Magnus Joakim Hansson

Rhonan Lee Ford

Antonio Kuok Keong Vong

Karl Henrik Johannes Ehinger

Mats Eskil Elmér

Karl Fredrik Lennart Sjovall

David Arthur Scowen

Derek Gregory Batcheller

Kari Henrik Johannes Ehinger

Mats Eskil ELMÉR

Karl Fredrik Lennart SJÖVALL

The present invention relates to novel cycloundecadepsipeptide compounds and their analogues which bind and inhibit cyclophilins, have reduced immunosuppressive activity and improved physicochemical properties including water solubility. The present invention further relates to pharmaceutical compositions containing said depsipeptide compounds and their analogues for use in the treatment or prevention of diseases and pathologies which may be ameliorated by the inhibition of cyclophilin activity.

Cyclic depsipeptide compounds and their uses

Disclosed herein are mono or di-succinate compounds where one or both of the acid groups in the succinate core are protected in the form of biologically labile moieties, and the use of said compounds to enhance mitochondrial function. The compounds may be of formula (I) wherein Ris H or an optionally substituted alkyl group or a group of formula (II) and Ris independently a group according to formula (II) where formula (II) is as defined 10 herein. 

Protected succinates for enhancing mitochondrial ATP-production

The present invention relates to novel cycloundecadepsipeptide compounds and their analoges which bind and inhibit cyclophilins, have reduced immunosuppressive activity and improved physicochemical properties including water solubility. The present invention further relates to pharmaceutical compositions containing said depsipeptide compounds and their analoges for use in the treatment or prevention of diseases and pathologies which may be ameliorated by the inhibition of cyclophilin activity.

Growing community of inventors

Ongar, United Kingdom

Hans Georg Fliri